Press coverage about Humanigen (NASDAQ:KBIO) has trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Humanigen earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 48.1471909992086 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Humanigen (NASDAQ KBIO) traded up 26.81% during midday trading on Friday, hitting $2.19. Humanigen has a one year low of $1.50 and a one year high of $4.75. The company has a 50-day moving average price of $1.84 and a 200 day moving average price of $2.45.

ILLEGAL ACTIVITY NOTICE: “Humanigen (KBIO) Receiving Somewhat Positive Media Coverage, Analysis Finds” was first published by Watch List News and is owned by of Watch List News. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at

About Humanigen

Humanigen, Inc, formerly KaloBios Pharmaceuticals, Inc, is a biopharmaceutical company. The Company focuses on developing medicines for patients with neglected and rare diseases, with an ancillary focus on pediatric conditions. The Company’s product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal and neurological problems.

Insider Buying and Selling by Quarter for Humanigen (NASDAQ:KBIO)

Receive News & Ratings for Humanigen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.